
17.AAG Predicted vs Actual Efficacy
pathway only (R2= 0.15)
Actual Efficacy
6.0
7.0
8.0
6.6
6.8
7.0
7.2
7.4
7.6
Precticted Efficacy


17.AAG Predicted vs Actual Efficacy
subtype only (R2= 0.11)
Actual Efficacy
6.0
7.0
8.0
6.9
7.0
7.1
7.2
7.3
7.4
7.5
7.6
Precticted Efficacy


17.AAG Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.15)
Actual Efficacy
6.0
7.0
8.0
6.6
6.8
7.0
7.2
7.4
7.6
Precticted Efficacy


5.FU Predicted vs Actual Efficacy
pathway only (R2= 0.15)
Actual Efficacy
Precticted Efficacy
2
3
4
5
3.4
3.6
3.8
4.0
4.2
4.4
4.6


5.FU Predicted vs Actual Efficacy
subtype only (R2= 0.04)
Actual Efficacy
Precticted Efficacy
2
3
4
5
3.8
3.9
4.0
4.1
4.2


5.FU Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.38)
Actual Efficacy
Precticted Efficacy
2
3
4
5
3.5
4.0
4.5
5.0


5.FdUR Predicted vs Actual Efficacy
pathway only (R2= 0.14)
Actual Efficacy
3.0
4.0
5.0
3.4
3.6
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


5.FdUR Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
3.0
4.0
5.0
3.6
3.8
4.0
4.2
Precticted Efficacy


5.FdUR Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.37)
Actual Efficacy
3.0
4.0
5.0
3.5
4.0
4.5
5.0
Precticted Efficacy


AG1478 Predicted vs Actual Efficacy
pathway only (R2= 0.22)
Actual Efficacy
Precticted Efficacy
4.0
5.0
6.0
7.0
4.0
4.5
5.0
5.5
6.0


AG1478 Predicted vs Actual Efficacy
subtype only (R2= 0.44)
Actual Efficacy
Precticted Efficacy
4.0
5.0
6.0
7.0
4.0
4.5
5.0
5.5
6.0
6.5


AG1478 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.81)
Actual Efficacy
Precticted Efficacy
4.0
5.0
6.0
7.0
4.0
4.5
5.0
5.5
6.0
6.5
7.0


Sigma.AKT1.2.inhibitor Predicted vs Actual Efficacy
pathway only (R2= 0.57)
Actual Efficacy
4.8
5.2
5.6
6.0
5.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


Sigma.AKT1.2.inhibitor Predicted vs Actual Efficacy
subtype only (R2= 0.53)
Actual Efficacy
4.8
5.2
5.6
6.0
5.0
5.2
5.4
5.6
Precticted Efficacy


Sigma.AKT1.2.inhibitor Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.75)
Actual Efficacy
4.8
5.2
5.6
6.0
5.0
5.5
6.0
Precticted Efficacy


Triciribine Predicted vs Actual Efficacy
pathway only (R2= 0.16)
Actual Efficacy
4.5
5.5
6.5
5.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


Triciribine Predicted vs Actual Efficacy
subtype only (R2= 0.24)
Actual Efficacy
4.5
5.5
6.5
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
Precticted Efficacy


Triciribine Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.16)
Actual Efficacy
4.5
5.5
6.5
5.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


AS.252424 Predicted vs Actual Efficacy
pathway only (R2= 0.25)
Actual Efficacy
4.2
4.6
5.0
5.4
4.4
4.6
4.8
5.0
Precticted Efficacy


AS.252424 Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
4.2
4.6
5.0
5.4
4.5
4.6
4.7
4.8
4.9
Precticted Efficacy


AS.252424 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.25)
Actual Efficacy
4.2
4.6
5.0
5.4
4.4
4.6
4.8
5.0
Precticted Efficacy


AZD6244 Predicted vs Actual Efficacy
pathway only (R2= 0.44)
Actual Efficacy
4.5
5.5
6.5
4.0
4.5
5.0
5.5
6.0
Precticted Efficacy


AZD6244 Predicted vs Actual Efficacy
subtype only (R2= 0.47)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


AZD6244 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.59)
Actual Efficacy
4.5
5.5
6.5
4.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


BEZ235 Predicted vs Actual Efficacy
pathway only (R2= 0.23)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


BEZ235 Predicted vs Actual Efficacy
subtype only (R2= 0.24)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


BEZ235 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.44)
Actual Efficacy
4.5
5.5
6.5
4.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


BIBW2992 Predicted vs Actual Efficacy
pathway only (R2= 0.34)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
7.5
8.5


BIBW2992 Predicted vs Actual Efficacy
subtype only (R2= 0.17)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
7.5
8.5


BIBW2992 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.9)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
7.5
8.0
8.5


Baicalein Predicted vs Actual Efficacy
pathway only (R2= 0.18)
Actual Efficacy
3.8
4.2
4.6
4.0
4.1
4.2
4.3
4.4
4.5
4.6
Precticted Efficacy


Baicalein Predicted vs Actual Efficacy
subtype only (R2= 0.16)
Actual Efficacy
3.8
4.2
4.6
4.2
4.3
4.4
4.5
4.6
Precticted Efficacy


Baicalein Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.32)
Actual Efficacy
3.8
4.2
4.6
4.1
4.2
4.3
4.4
4.5
4.6
Precticted Efficacy


Bortezomib Predicted vs Actual Efficacy
pathway only (R2= 0.11)
Actual Efficacy
5.5
6.5
7.5
8.5
7.4
7.6
7.8
8.0
8.2
Precticted Efficacy


Bortezomib Predicted vs Actual Efficacy
subtype only (R2= 0.07)
Actual Efficacy
5.5
6.5
7.5
8.5
7.7
7.8
7.9
8.0
Precticted Efficacy


Bortezomib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.11)
Actual Efficacy
5.5
6.5
7.5
8.5
7.4
7.6
7.8
8.0
8.2
Precticted Efficacy


CGC.11047 Predicted vs Actual Efficacy
pathway only (R2= 0.21)
Actual Efficacy
3
4
5
6
3.5
4.0
4.5
Precticted Efficacy


CGC.11047 Predicted vs Actual Efficacy
subtype only (R2= 0.31)
Actual Efficacy
3
4
5
6
3.8
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


CGC.11047 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.21)
Actual Efficacy
3
4
5
6
3.5
4.0
4.5
Precticted Efficacy


CGC.11144 Predicted vs Actual Efficacy
pathway only (R2= 0)
Actual Efficacy
7.0
6.0
5.0
6.12
6.14
6.16
6.18
6.20
6.22
Precticted Efficacy


CGC.11144 Predicted vs Actual Efficacy
subtype only (R2= 0.06)
Actual Efficacy
7.0
6.0
5.0
5.9
6.0
6.1
6.2
Precticted Efficacy


CGC.11144 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.23)
Actual Efficacy
7.0
6.0
5.0
5.6
5.8
6.0
6.2
6.4
6.6
Precticted Efficacy


CPT.11 Predicted vs Actual Efficacy
pathway only (R2= 0.51)
Actual Efficacy
4.5
5.5
4.5
5.0
5.5
6.0
Precticted Efficacy


CPT.11 Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
4.5
5.5
5.0
5.1
5.2
5.3
5.4
5.5
Precticted Efficacy


CPT.11 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.51)
Actual Efficacy
4.5
5.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Carboplatin Predicted vs Actual Efficacy
pathway only (R2= 0.21)
Actual Efficacy
3.0
4.0
5.0
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


Carboplatin Predicted vs Actual Efficacy
subtype only (R2= 0.07)
Actual Efficacy
3.0
4.0
5.0
4.20
4.25
4.30
4.35
4.40
4.45
4.50
4.55
Precticted Efficacy


Carboplatin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.4)
Actual Efficacy
3.0
4.0
5.0
3.8
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


Cisplatin Predicted vs Actual Efficacy
pathway only (R2= 0.31)
Actual Efficacy
3.5
4.5
5.5
4.5
5.0
5.5
Precticted Efficacy


Cisplatin Predicted vs Actual Efficacy
subtype only (R2= 0.19)
Actual Efficacy
3.5
4.5
5.5
4.7
4.8
4.9
5.0
5.1
5.2
5.3
5.4
Precticted Efficacy


Cisplatin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.44)
Actual Efficacy
3.5
4.5
5.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Disulfiram Predicted vs Actual Efficacy
pathway only (R2= 0.2)
Actual Efficacy
4.5
5.5
6.5
4.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


Disulfiram Predicted vs Actual Efficacy
subtype only (R2= 0.12)
Actual Efficacy
4.5
5.5
6.5
4.8
5.0
5.2
5.4
5.6
Precticted Efficacy


Disulfiram Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.2)
Actual Efficacy
4.5
5.5
6.5
4.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


Docetaxel Predicted vs Actual Efficacy
pathway only (R2= 0.1)
Actual Efficacy
6.5
7.5
8.5
8.0
8.2
8.4
8.6
Precticted Efficacy


Docetaxel Predicted vs Actual Efficacy
subtype only (R2= 0.14)
Actual Efficacy
6.5
7.5
8.5
8.1
8.2
8.3
8.4
8.5
Precticted Efficacy


Docetaxel Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.1)
Actual Efficacy
6.5
7.5
8.5
8.0
8.2
8.4
8.6
Precticted Efficacy


Doxorubicin Predicted vs Actual Efficacy
pathway only (R2= 0.36)
Actual Efficacy
5.5
6.0
6.5
7.0
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


Doxorubicin Predicted vs Actual Efficacy
subtype only (R2= 0.15)
Actual Efficacy
5.5
6.0
6.5
7.0
6.4
6.5
6.6
6.7
6.8
6.9
Precticted Efficacy


Doxorubicin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.36)
Actual Efficacy
5.5
6.0
6.5
7.0
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


ERKi.II..FR180304. Predicted vs Actual Efficacy
pathway only (R2= 0.1)
Actual Efficacy
Precticted Efficacy
4.0
4.4
4.8
5.2
4.35
4.40
4.45
4.50
4.55
4.60


ERKi.II..FR180304. Predicted vs Actual Efficacy
subtype only (R2= 0.05)
Actual Efficacy
Precticted Efficacy
4.0
4.4
4.8
5.2
4.35
4.40
4.45
4.50


ERKi.II..FR180304. Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.1)
Actual Efficacy
Precticted Efficacy
4.0
4.4
4.8
5.2
4.35
4.40
4.45
4.50
4.55
4.60


Epirubicin Predicted vs Actual Efficacy
pathway only (R2= 0.38)
Actual Efficacy
5.5
6.5
7.5
6.0
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


Epirubicin Predicted vs Actual Efficacy
subtype only (R2= 0.16)
Actual Efficacy
5.5
6.5
7.5
6.5
6.6
6.7
6.8
6.9
7.0
Precticted Efficacy


Epirubicin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.38)
Actual Efficacy
5.5
6.5
7.5
6.0
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


Erlotinib Predicted vs Actual Efficacy
pathway only (R2= 0.47)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Erlotinib Predicted vs Actual Efficacy
subtype only (R2= 0.68)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Erlotinib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.77)
Actual Efficacy
4.5
5.5
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Etoposide Predicted vs Actual Efficacy
pathway only (R2= 0.09)
Actual Efficacy
Precticted Efficacy
3.5
4.5
5.5
6.5
5.2
5.3
5.4
5.5
5.6
5.7
5.8


Etoposide Predicted vs Actual Efficacy
subtype only (R2= 0.08)
Actual Efficacy
Precticted Efficacy
3.5
4.5
5.5
6.5
5.3
5.4
5.5
5.6
5.7


Etoposide Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.09)
Actual Efficacy
Precticted Efficacy
3.5
4.5
5.5
6.5
5.2
5.3
5.4
5.5
5.6
5.7
5.8


Everolimus Predicted vs Actual Efficacy
pathway only (R2= 0.36)
Actual Efficacy
Precticted Efficacy
5.0
5.5
6.0
6.5
7.0
7.5
5
6
7
8


Everolimus Predicted vs Actual Efficacy
subtype only (R2= 0.38)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
5
6
7
8


Everolimus Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.36)
Actual Efficacy
Precticted Efficacy
5.0
5.5
6.0
6.5
7.0
7.5
5
6
7
8


FTase.inhibitor.I Predicted vs Actual Efficacy
pathway only (R2= 0.13)
Actual Efficacy
4.2
4.4
4.6
4.8
4.25
4.30
4.35
4.40
4.45
4.50
Precticted Efficacy


FTase.inhibitor.I Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
4.2
4.4
4.6
4.8
4.30
4.35
4.40
4.45
Precticted Efficacy


FTase.inhibitor.I Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.47)
Actual Efficacy
4.2
4.4
4.6
4.8
4.2
4.3
4.4
4.5
4.6
Precticted Efficacy


Fascaplysin Predicted vs Actual Efficacy
pathway only (R2= 0.31)
Actual Efficacy
6.0
7.0
8.0
6.3
6.4
6.5
6.6
6.7
6.8
6.9
Precticted Efficacy


Fascaplysin Predicted vs Actual Efficacy
subtype only (R2= 0.28)
Actual Efficacy
6.0
7.0
8.0
6.4
6.5
6.6
6.7
6.8
Precticted Efficacy


Fascaplysin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.31)
Actual Efficacy
6.0
7.0
8.0
6.3
6.4
6.5
6.6
6.7
6.8
6.9
Precticted Efficacy


GSK923295 Predicted vs Actual Efficacy
pathway only (R2= 0.1)
Actual Efficacy
4.5
5.5
6.5
7.5
6.4
6.6
6.8
7.0
7.2
7.4
Precticted Efficacy


GSK923295 Predicted vs Actual Efficacy
subtype only (R2= 0.19)
Actual Efficacy
4.5
5.5
6.5
7.5
6.0
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


GSK923295 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.35)
Actual Efficacy
4.5
5.5
6.5
7.5
5.5
6.0
6.5
7.0
7.5
Precticted Efficacy


GSK1070916 Predicted vs Actual Efficacy
pathway only (R2= 0.44)
Actual Efficacy
5.0
5.5
6.0
6.5
5.2
5.4
5.6
5.8
6.0
6.2
6.4
Precticted Efficacy


GSK1070916 Predicted vs Actual Efficacy
subtype only (R2= 0.17)
Actual Efficacy
5.0
5.5
6.0
6.5
5.4
5.5
5.6
5.7
5.8
Precticted Efficacy


GSK1070916 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.44)
Actual Efficacy
5.0
5.5
6.0
6.5
5.2
5.4
5.6
5.8
6.0
6.2
6.4
Precticted Efficacy


GSK1120212 Predicted vs Actual Efficacy
pathway only (R2= 0.38)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.0
5.5
6.0
6.5
7.0
7.5
8.0


GSK1120212 Predicted vs Actual Efficacy
subtype only (R2= 0.36)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.5
6.0
6.5
7.0
7.5
8.0
8.5


GSK1120212 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.38)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.0
5.5
6.0
6.5
7.0
7.5
8.0


GSK1059868 Predicted vs Actual Efficacy
pathway only (R2= 0.37)
Actual Efficacy
4.5
5.0
5.5
6.0
4.6
4.8
5.0
5.2
Precticted Efficacy


GSK1059868 Predicted vs Actual Efficacy
subtype only (R2= 0.18)
Actual Efficacy
4.5
5.0
5.5
6.0
4.6
4.7
4.8
4.9
5.0
Precticted Efficacy


GSK1059868 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.53)
Actual Efficacy
4.5
5.0
5.5
6.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


GSK1838705 Predicted vs Actual Efficacy
pathway only (R2= 0.29)
Actual Efficacy
4.0
5.0
6.0
4.8
5.0
5.2
5.4
5.6
5.8
Precticted Efficacy


GSK1838705 Predicted vs Actual Efficacy
subtype only (R2= 0.26)
Actual Efficacy
4.0
5.0
6.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


GSK1838705 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.49)
Actual Efficacy
4.0
5.0
6.0
5.0
5.5
6.0
Precticted Efficacy


GSK461364 Predicted vs Actual Efficacy
pathway only (R2= 0.15)
Actual Efficacy
Precticted Efficacy
5
6
7
8
9
6.5
7.0
7.5


GSK461364 Predicted vs Actual Efficacy
subtype only (R2= 0.23)
Actual Efficacy
Precticted Efficacy
5
6
7
8
9
6.4
6.6
6.8
7.0
7.2
7.4
7.6
7.8


GSK461364 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
Precticted Efficacy
5
6
7
8
9
6.0
6.5
7.0
7.5
8.0


GSK2119563 Predicted vs Actual Efficacy
pathway only (R2= 0.37)
Actual Efficacy
4.5
5.5
6.5
7.5
5.0
5.5
6.0
6.5
7.0
Precticted Efficacy


GSK2119563 Predicted vs Actual Efficacy
subtype only (R2= 0.38)
Actual Efficacy
4.5
5.5
6.5
7.5
5.5
6.0
6.5
Precticted Efficacy


GSK2119563 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.37)
Actual Efficacy
4.5
5.5
6.5
7.5
5.0
5.5
6.0
6.5
7.0
Precticted Efficacy


GSK2126458 Predicted vs Actual Efficacy
pathway only (R2= 0.39)
Actual Efficacy
6.5
7.5
8.5
9.5
7.0
7.5
8.0
8.5
Precticted Efficacy


GSK2126458 Predicted vs Actual Efficacy
subtype only (R2= 0.45)
Actual Efficacy
6.5
7.5
8.5
9.5
7.2
7.4
7.6
7.8
8.0
8.2
8.4
Precticted Efficacy


GSK2126458 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.56)
Actual Efficacy
6.5
7.5
8.5
9.5
7.0
7.5
8.0
8.5
Precticted Efficacy


GSK2141795 Predicted vs Actual Efficacy
pathway only (R2= 0.44)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.5
6.0
6.5
7.0
7.5


GSK2141795 Predicted vs Actual Efficacy
subtype only (R2= 0.25)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.4
5.6
5.8
6.0
6.2
6.4
6.6
6.8


GSK2141795 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.44)
Actual Efficacy
Precticted Efficacy
5
6
7
8
5.5
6.0
6.5
7.0
7.5


GSK1059615 Predicted vs Actual Efficacy
pathway only (R2= 0.17)
Actual Efficacy
5.5
6.5
7.5
5.8
6.0
6.2
6.4
6.6
6.8
Precticted Efficacy


GSK1059615 Predicted vs Actual Efficacy
subtype only (R2= 0.35)
Actual Efficacy
5.5
6.5
7.5
5.8
6.0
6.2
6.4
6.6
6.8
Precticted Efficacy


GSK1059615 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.42)
Actual Efficacy
5.5
6.5
7.5
5.8
6.0
6.2
6.4
6.6
6.8
Precticted Efficacy


GSK650394 Predicted vs Actual Efficacy
pathway only (R2= 0.55)
Actual Efficacy
4.5
5.0
5.5
6.0
4.0
4.5
5.0
Precticted Efficacy


GSK650394 Predicted vs Actual Efficacy
subtype only (R2= 0.51)
Actual Efficacy
4.5
5.0
5.5
6.0
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


GSK650394 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.7)
Actual Efficacy
4.5
5.0
5.5
6.0
4.0
4.5
5.0
5.5
Precticted Efficacy


Lapatinib Predicted vs Actual Efficacy
pathway only (R2= 0.42)
Actual Efficacy
5.0
5.5
6.0
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Lapatinib Predicted vs Actual Efficacy
subtype only (R2= 0.14)
Actual Efficacy
5.0
5.5
6.0
6.5
4.8
4.9
5.0
5.1
5.2
5.3
5.4
Precticted Efficacy


Lapatinib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.85)
Actual Efficacy
5.0
5.5
6.0
6.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Geldanamycin Predicted vs Actual Efficacy
pathway only (R2= 0.15)
Actual Efficacy
7.0
7.5
8.0
7.2
7.4
7.6
7.8
Precticted Efficacy


Geldanamycin Predicted vs Actual Efficacy
subtype only (R2= 0.17)
Actual Efficacy
7.0
7.5
8.0
7.6
7.7
7.8
7.9
8.0
8.1
Precticted Efficacy


Geldanamycin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.61)
Actual Efficacy
7.0
7.5
8.0
7.0
7.5
8.0
Precticted Efficacy


Gemcitabine Predicted vs Actual Efficacy
pathway only (R2= 0.29)
Actual Efficacy
Precticted Efficacy


Gemcitabine Predicted vs Actual Efficacy
subtype only (R2= 0.03)
Actual Efficacy
Precticted Efficacy


Gemcitabine Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.29)
Actual Efficacy
Precticted Efficacy


Glycyl.H1152 Predicted vs Actual Efficacy
pathway only (R2= 0.23)
Actual Efficacy
4.5
5.5
4.2
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


Glycyl.H1152 Predicted vs Actual Efficacy
subtype only (R2= 0.12)
Actual Efficacy
4.5
5.5
4.6
4.8
5.0
5.2
Precticted Efficacy


Glycyl.H1152 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.23)
Actual Efficacy
4.5
5.5
4.2
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


ICRF.193 Predicted vs Actual Efficacy
pathway only (R2= 0.14)
Actual Efficacy
4.5
5.5
6.5
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
Precticted Efficacy


ICRF.193 Predicted vs Actual Efficacy
subtype only (R2= 0.05)
Actual Efficacy
4.5
5.5
6.5
4.9
5.0
5.1
5.2
5.3
Precticted Efficacy


ICRF.193 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.14)
Actual Efficacy
4.5
5.5
6.5
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
Precticted Efficacy


IKK.16 Predicted vs Actual Efficacy
pathway only (R2= 0.49)
Actual Efficacy
Precticted Efficacy
5.2
5.6
6.0
5.2
5.4
5.6
5.8


IKK.16 Predicted vs Actual Efficacy
subtype only (R2= 0.25)
Actual Efficacy
Precticted Efficacy
5.2
5.6
6.0
5.40
5.45
5.50
5.55
5.60
5.65


IKK.16 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.61)
Actual Efficacy
Precticted Efficacy
5.2
5.6
6.0
5.2
5.4
5.6
5.8


Ibandronate.sodium.salt Predicted vs Actual Efficacy
pathway only (R2= 0.27)
Actual Efficacy
3.5
4.0
4.5
5.0
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


Ibandronate.sodium.salt Predicted vs Actual Efficacy
subtype only (R2= 0.34)
Actual Efficacy
3.5
4.0
4.5
5.0
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


Ibandronate.sodium.salt Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
3.5
4.0
4.5
5.0
3.6
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


Imatinib Predicted vs Actual Efficacy
pathway only (R2= 0.11)
Actual Efficacy
4.0
4.5
5.0
5.5
4.5
4.6
4.7
4.8
4.9
Precticted Efficacy


Imatinib Predicted vs Actual Efficacy
subtype only (R2= 0.09)
Actual Efficacy
4.0
4.5
5.0
5.5
4.55
4.60
4.65
4.70
4.75
4.80
Precticted Efficacy


Imatinib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.3)
Actual Efficacy
4.0
4.5
5.0
5.5
4.4
4.5
4.6
4.7
4.8
4.9
5.0
Precticted Efficacy


Gefitinib Predicted vs Actual Efficacy
pathway only (R2= 0.19)
Actual Efficacy
Precticted Efficacy
4.5
5.5
6.5
7.5
5.0
5.5
6.0


Gefitinib Predicted vs Actual Efficacy
subtype only (R2= 0.26)
Actual Efficacy
Precticted Efficacy
4.5
5.5
6.5
7.5
4.8
5.0
5.2
5.4
5.6
5.8
6.0


Gefitinib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.59)
Actual Efficacy
Precticted Efficacy
4.5
5.5
6.5
7.5
4.5
5.0
5.5
6.0


Ixabepilone Predicted vs Actual Efficacy
pathway only (R2= 0.08)
Actual Efficacy
5
6
7
8
9
7.4
7.6
7.8
8.0
8.2
8.4
Precticted Efficacy


Ixabepilone Predicted vs Actual Efficacy
subtype only (R2= 0.09)
Actual Efficacy
5
6
7
8
9
7.6
7.8
8.0
8.2
8.4
Precticted Efficacy


Ixabepilone Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.08)
Actual Efficacy
5
6
7
8
9
7.4
7.6
7.8
8.0
8.2
8.4
Precticted Efficacy


LBH589 Predicted vs Actual Efficacy
pathway only (R2= 0.45)
Actual Efficacy
6.0
6.4
6.8
7.2
6.4
6.6
6.8
7.0
Precticted Efficacy


LBH589 Predicted vs Actual Efficacy
subtype only (R2= 0.28)
Actual Efficacy
6.0
6.4
6.8
7.2
6.6
6.7
6.8
6.9
7.0
Precticted Efficacy


LBH589 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.61)
Actual Efficacy
6.0
6.4
6.8
7.2
6.2
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


Lestaurtinib.CEP.701. Predicted vs Actual Efficacy
pathway only (R2= 0.14)
Actual Efficacy
5.0
6.0
7.0
5.9
6.0
6.1
6.2
6.3
6.4
6.5
Precticted Efficacy


Lestaurtinib.CEP.701. Predicted vs Actual Efficacy
subtype only (R2= 0.08)
Actual Efficacy
5.0
6.0
7.0
6.1
6.2
6.3
6.4
Precticted Efficacy


Lestaurtinib.CEP.701. Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.32)
Actual Efficacy
5.0
6.0
7.0
5.6
5.8
6.0
6.2
6.4
6.6
Precticted Efficacy


MG.132 Predicted vs Actual Efficacy
pathway only (R2= 0.5)
Actual Efficacy
6.5
7.0
7.5
6.4
6.6
6.8
7.0
7.2
Precticted Efficacy


MG.132 Predicted vs Actual Efficacy
subtype only (R2= 0.55)
Actual Efficacy
6.5
7.0
7.5
6.8
7.0
7.2
7.4
Precticted Efficacy


MG.132 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.8)
Actual Efficacy
6.5
7.0
7.5
6.4
6.6
6.8
7.0
7.2
7.4
7.6
Precticted Efficacy


MLN4924 Predicted vs Actual Efficacy
pathway only (R2= 0.37)
Actual Efficacy
5.0
6.0
7.0
5.5
6.0
6.5
7.0
Precticted Efficacy


MLN4924 Predicted vs Actual Efficacy
subtype only (R2= 0.1)
Actual Efficacy
5.0
6.0
7.0
6.1
6.2
6.3
6.4
6.5
6.6
Precticted Efficacy


MLN4924 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.37)
Actual Efficacy
5.0
6.0
7.0
5.5
6.0
6.5
7.0
Precticted Efficacy


Mebendazole Predicted vs Actual Efficacy
pathway only (R2= 0.16)
Actual Efficacy
4.5
5.5
6.5
5.4
5.6
5.8
6.0
6.2
6.4
6.6
Precticted Efficacy


Mebendazole Predicted vs Actual Efficacy
subtype only (R2= 0.22)
Actual Efficacy
4.5
5.5
6.5
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
Precticted Efficacy


Mebendazole Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.28)
Actual Efficacy
4.5
5.5
6.5
5.0
5.5
6.0
6.5
Precticted Efficacy


Methotrexate Predicted vs Actual Efficacy
pathway only (R2= 0.2)
Actual Efficacy
Precticted Efficacy


Methotrexate Predicted vs Actual Efficacy
subtype only (R2= 0.23)
Actual Efficacy
Precticted Efficacy


Methotrexate Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
Precticted Efficacy


NSC663284 Predicted vs Actual Efficacy
pathway only (R2= 0)
Actual Efficacy
5.2
5.6
6.0
5.58
5.60
5.62
5.64
5.66
5.68
Precticted Efficacy


NSC663284 Predicted vs Actual Efficacy
subtype only (R2= 0.01)
Actual Efficacy
5.2
5.6
6.0
5.60
5.62
5.64
5.66
5.68
Precticted Efficacy


NSC663284 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0)
Actual Efficacy
5.2
5.6
6.0
5.58
5.60
5.62
5.64
5.66
5.68
Precticted Efficacy


NU6102 Predicted vs Actual Efficacy
pathway only (R2= 0.36)
Actual Efficacy
4.4
4.8
5.2
4.5
4.6
4.7
4.8
4.9
5.0
5.1
Precticted Efficacy


NU6102 Predicted vs Actual Efficacy
subtype only (R2= 0.25)
Actual Efficacy
4.4
4.8
5.2
4.7
4.8
4.9
5.0
5.1
Precticted Efficacy


NU6102 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.36)
Actual Efficacy
4.4
4.8
5.2
4.5
4.6
4.7
4.8
4.9
5.0
5.1
Precticted Efficacy


Nelfinavir Predicted vs Actual Efficacy
pathway only (R2= 0)
Actual Efficacy
4.6
5.0
5.4
4.94
4.96
4.98
5.00
5.02
5.04
Precticted Efficacy


Nelfinavir Predicted vs Actual Efficacy
subtype only (R2= 0.07)
Actual Efficacy
4.6
5.0
5.4
4.85
4.90
4.95
5.00
5.05
Precticted Efficacy


Nelfinavir Predicted vs Actual Efficacy
Pathway + subtype (R2= 0)
Actual Efficacy
4.6
5.0
5.4
4.94
4.96
4.98
5.00
5.02
5.04
Precticted Efficacy


Nutlin.3a Predicted vs Actual Efficacy
pathway only (R2= 0.27)
Actual Efficacy
4.5
5.0
5.5
4.4
4.6
4.8
5.0
5.2
Precticted Efficacy


Nutlin.3a Predicted vs Actual Efficacy
subtype only (R2= 0.4)
Actual Efficacy
4.5
5.0
5.5
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


Nutlin.3a Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.5)
Actual Efficacy
4.5
5.0
5.5
4.2
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


Olomoucine.II Predicted vs Actual Efficacy
pathway only (R2= 0.36)
Actual Efficacy
5.0
5.2
5.4
5.6
5.1
5.2
5.3
5.4
5.5
Precticted Efficacy


Olomoucine.II Predicted vs Actual Efficacy
subtype only (R2= 0.18)
Actual Efficacy
5.0
5.2
5.4
5.6
5.25
5.30
5.35
5.40
5.45
Precticted Efficacy


Olomoucine.II Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.52)
Actual Efficacy
5.0
5.2
5.4
5.6
5.0
5.1
5.2
5.3
5.4
5.5
Precticted Efficacy


Oxaliplatin Predicted vs Actual Efficacy
pathway only (R2= 0.39)
Actual Efficacy
3.5
4.5
5.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Oxaliplatin Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
3.5
4.5
5.5
5.0
5.1
5.2
5.3
5.4
5.5
5.6
Precticted Efficacy


Oxaliplatin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
3.5
4.5
5.5
4.5
5.0
5.5
6.0
Precticted Efficacy


Oxamflatin Predicted vs Actual Efficacy
pathway only (R2= 0.19)
Actual Efficacy
5.4
5.8
6.2
6.6
5.9
6.0
6.1
6.2
Precticted Efficacy


Oxamflatin Predicted vs Actual Efficacy
subtype only (R2= 0.06)
Actual Efficacy
5.4
5.8
6.2
6.6
5.85
5.90
5.95
6.00
6.05
Precticted Efficacy


Oxamflatin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.19)
Actual Efficacy
5.4
5.8
6.2
6.6
5.9
6.0
6.1
6.2
Precticted Efficacy


PD98059 Predicted vs Actual Efficacy
pathway only (R2= 0.42)
Actual Efficacy
4.0
4.4
4.8
4.1
4.2
4.3
4.4
4.5
4.6
4.7
Precticted Efficacy


PD98059 Predicted vs Actual Efficacy
subtype only (R2= 0.09)
Actual Efficacy
4.0
4.4
4.8
4.25
4.30
4.35
4.40
Precticted Efficacy


PD98059 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.42)
Actual Efficacy
4.0
4.4
4.8
4.1
4.2
4.3
4.4
4.5
4.6
4.7
Precticted Efficacy


PF.2341066 Predicted vs Actual Efficacy
pathway only (R2= 0.21)
Actual Efficacy
5.0
5.5
6.0
5.2
5.3
5.4
5.5
5.6
5.7
5.8
Precticted Efficacy


PF.2341066 Predicted vs Actual Efficacy
subtype only (R2= 0.01)
Actual Efficacy
5.0
5.5
6.0
5.48
5.50
5.52
5.54
Precticted Efficacy


PF.2341066 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.53)
Actual Efficacy
5.0
5.5
6.0
5.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


PF.3084014 Predicted vs Actual Efficacy
pathway only (R2= 0.25)
Actual Efficacy
4.5
5.5
6.5
4.2
4.4
4.6
4.8
5.0
5.2
Precticted Efficacy


PF.3084014 Predicted vs Actual Efficacy
subtype only (R2= 0.08)
Actual Efficacy
4.5
5.5
6.5
4.3
4.4
4.5
4.6
4.7
Precticted Efficacy


PF.3084014 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.25)
Actual Efficacy
4.5
5.5
6.5
4.2
4.4
4.6
4.8
5.0
5.2
Precticted Efficacy


PF.3814735 Predicted vs Actual Efficacy
pathway only (R2= 0.33)
Actual Efficacy
5.0
6.0
7.0
5.2
5.4
5.6
5.8
6.0
6.2
Precticted Efficacy


PF.3814735 Predicted vs Actual Efficacy
subtype only (R2= 0.1)
Actual Efficacy
5.0
6.0
7.0
5.5
5.6
5.7
5.8
Precticted Efficacy


PF.3814735 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.33)
Actual Efficacy
5.0
6.0
7.0
5.2
5.4
5.6
5.8
6.0
6.2
Precticted Efficacy


PF.4691502 Predicted vs Actual Efficacy
pathway only (R2= 0.41)
Actual Efficacy
5.0
6.0
7.0
6.2
6.4
6.6
6.8
7.0
7.2
7.4
Precticted Efficacy


PF.4691502 Predicted vs Actual Efficacy
subtype only (R2= 0.31)
Actual Efficacy
5.0
6.0
7.0
6.4
6.6
6.8
7.0
Precticted Efficacy


PF.4691502 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.41)
Actual Efficacy
5.0
6.0
7.0
6.2
6.4
6.6
6.8
7.0
7.2
7.4
Precticted Efficacy


Paclitaxel Predicted vs Actual Efficacy
pathway only (R2= 0.12)
Actual Efficacy
7.0
7.4
7.8
8.2
7.75
7.80
7.85
7.90
7.95
8.00
8.05
Precticted Efficacy


Paclitaxel Predicted vs Actual Efficacy
subtype only (R2= 0.15)
Actual Efficacy
7.0
7.4
7.8
8.2
7.80
7.85
7.90
7.95
8.00
8.05
8.10
8.15
Precticted Efficacy


Paclitaxel Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.32)
Actual Efficacy
7.0
7.4
7.8
8.2
7.6
7.7
7.8
7.9
8.0
8.1
8.2
Precticted Efficacy


Pemetrexed Predicted vs Actual Efficacy
pathway only (R2= 0.23)
Actual Efficacy
3
4
5
6
2.0
2.5
3.0
3.5
4.0
4.5
Precticted Efficacy


Pemetrexed Predicted vs Actual Efficacy
subtype only (R2= 0.15)
Actual Efficacy
3
4
5
6
3.0
3.5
4.0
4.5
Precticted Efficacy


Pemetrexed Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.23)
Actual Efficacy
3
4
5
6
2.0
2.5
3.0
3.5
4.0
4.5
Precticted Efficacy


Purvalanol.A Predicted vs Actual Efficacy
pathway only (R2= 0.51)
Actual Efficacy
4.0
4.5
5.0
5.5
3.6
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


Purvalanol.A Predicted vs Actual Efficacy
subtype only (R2= 0.32)
Actual Efficacy
4.0
4.5
5.0
5.5
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


Purvalanol.A Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.51)
Actual Efficacy
4.0
4.5
5.0
5.5
3.6
3.8
4.0
4.2
4.4
4.6
Precticted Efficacy


L.779450 Predicted vs Actual Efficacy
pathway only (R2= 0.18)
Actual Efficacy
4.4
4.8
5.2
4.6
4.7
4.8
4.9
5.0
Precticted Efficacy


L.779450 Predicted vs Actual Efficacy
subtype only (R2= 0.21)
Actual Efficacy
4.4
4.8
5.2
4.7
4.8
4.9
5.0
Precticted Efficacy


L.779450 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.36)
Actual Efficacy
4.4
4.8
5.2
4.6
4.8
5.0
5.2
Precticted Efficacy


Rapamycin Predicted vs Actual Efficacy
pathway only (R2= 0.34)
Actual Efficacy
Precticted Efficacy


Rapamycin Predicted vs Actual Efficacy
subtype only (R2= 0.29)
Actual Efficacy
Precticted Efficacy


Rapamycin Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.28)
Actual Efficacy
Precticted Efficacy


Vorinostat Predicted vs Actual Efficacy
pathway only (R2= 0.39)
Actual Efficacy
3.5
4.0
4.5
5.0
3.6
3.8
4.0
4.2
4.4
Precticted Efficacy


Vorinostat Predicted vs Actual Efficacy
subtype only (R2= 0.34)
Actual Efficacy
3.5
4.0
4.5
5.0
3.7
3.8
3.9
4.0
4.1
4.2
Precticted Efficacy


Vorinostat Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
3.5
4.0
4.5
5.0
3.6
3.8
4.0
4.2
4.4
Precticted Efficacy


SB.3CT Predicted vs Actual Efficacy
pathway only (R2= 0.12)
Actual Efficacy
3.8
4.2
4.6
5.0
3.8
3.9
4.0
4.1
4.2
4.3
4.4
Precticted Efficacy


SB.3CT Predicted vs Actual Efficacy
subtype only (R2= 0.13)
Actual Efficacy
3.8
4.2
4.6
5.0
3.9
4.0
4.1
4.2
4.3
Precticted Efficacy


SB.3CT Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.12)
Actual Efficacy
3.8
4.2
4.6
5.0
3.8
3.9
4.0
4.1
4.2
4.3
4.4
Precticted Efficacy


Ispinesib Predicted vs Actual Efficacy
pathway only (R2= 0.2)
Actual Efficacy
5.5
6.5
7.5
6.6
6.8
7.0
7.2
7.4
7.6
7.8
Precticted Efficacy


Ispinesib Predicted vs Actual Efficacy
subtype only (R2= 0.07)
Actual Efficacy
5.5
6.5
7.5
6.9
7.0
7.1
7.2
7.3
Precticted Efficacy


Ispinesib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.2)
Actual Efficacy
5.5
6.5
7.5
6.6
6.8
7.0
7.2
7.4
7.6
7.8
Precticted Efficacy


Bosutinib Predicted vs Actual Efficacy
pathway only (R2= 0.28)
Actual Efficacy
4.0
5.0
6.0
5.3
5.4
5.5
5.6
5.7
5.8
5.9
6.0
Precticted Efficacy


Bosutinib Predicted vs Actual Efficacy
subtype only (R2= 0.27)
Actual Efficacy
4.0
5.0
6.0
5.5
5.6
5.7
5.8
5.9
6.0
Precticted Efficacy


Bosutinib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.47)
Actual Efficacy
4.0
5.0
6.0
5.0
5.2
5.4
5.6
5.8
6.0
Precticted Efficacy


Sorafenib Predicted vs Actual Efficacy
pathway only (R2= 0.42)
Actual Efficacy
3.0
4.0
5.0
4.0
4.5
5.0
Precticted Efficacy


Sorafenib Predicted vs Actual Efficacy
subtype only (R2= 0.25)
Actual Efficacy
3.0
4.0
5.0
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


Sorafenib Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.42)
Actual Efficacy
3.0
4.0
5.0
4.0
4.5
5.0
Precticted Efficacy


Sunitinib.Malate Predicted vs Actual Efficacy
pathway only (R2= 0.37)
Actual Efficacy
4.8
5.2
5.6
5.0
5.1
5.2
5.3
5.4
Precticted Efficacy


Sunitinib.Malate Predicted vs Actual Efficacy
subtype only (R2= 0.16)
Actual Efficacy
4.8
5.2
5.6
5.10
5.15
5.20
5.25
5.30
Precticted Efficacy


Sunitinib.Malate Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.53)
Actual Efficacy
4.8
5.2
5.6
4.8
5.0
5.2
5.4
5.6
Precticted Efficacy


TCS.PIM.11 Predicted vs Actual Efficacy
pathway only (R2= 0.54)
Actual Efficacy
4.0
4.5
5.0
5.5
3.6
3.8
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


TCS.PIM.11 Predicted vs Actual Efficacy
subtype only (R2= 0.34)
Actual Efficacy
4.0
4.5
5.0
5.5
4.0
4.2
4.4
4.6
Precticted Efficacy


TCS.PIM.11 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.67)
Actual Efficacy
4.0
4.5
5.0
5.5
3.6
3.8
4.0
4.2
4.4
4.6
4.8
5.0
Precticted Efficacy


TCS2312.dihydrochloride Predicted vs Actual Efficacy
pathway only (R2= 0.17)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
5.9
6.0
6.1
6.2
6.3
6.4
6.5


TCS2312.dihydrochloride Predicted vs Actual Efficacy
subtype only (R2= 0.16)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
6.1
6.2
6.3
6.4


TCS2312.dihydrochloride Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.44)
Actual Efficacy
Precticted Efficacy
5.5
6.0
6.5
7.0
5.8
6.0
6.2
6.4
6.6


Topotecan Predicted vs Actual Efficacy
pathway only (R2= 0.19)
Actual Efficacy
5
6
7
8
6.2
6.4
6.6
6.8
7.0
7.2
7.4
Precticted Efficacy


Topotecan Predicted vs Actual Efficacy
subtype only (R2= 0.02)
Actual Efficacy
5
6
7
8
6.7
6.8
6.9
7.0
7.1
Precticted Efficacy


Topotecan Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.19)
Actual Efficacy
5
6
7
8
6.2
6.4
6.6
6.8
7.0
7.2
7.4
Precticted Efficacy


Tamoxifen Predicted vs Actual Efficacy
pathway only (R2= 0.2)
Actual Efficacy
4.0
5.0
6.0
3.8
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


Tamoxifen Predicted vs Actual Efficacy
subtype only (R2= 0.09)
Actual Efficacy
4.0
5.0
6.0
4.0
4.1
4.2
4.3
4.4
4.5
Precticted Efficacy


Tamoxifen Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.2)
Actual Efficacy
4.0
5.0
6.0
3.8
4.0
4.2
4.4
4.6
4.8
Precticted Efficacy


Temsirolimus Predicted vs Actual Efficacy
pathway only (R2= 0.13)
Actual Efficacy
Precticted Efficacy
4
5
6
7
8
9
5.4
5.6
5.8
6.0
6.2
6.4


Temsirolimus Predicted vs Actual Efficacy
subtype only (R2= 0.18)
Actual Efficacy
Precticted Efficacy
4
5
6
7
8
9
5.4
5.6
5.8
6.0
6.2
6.4


Temsirolimus Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.13)
Actual Efficacy
Precticted Efficacy
4
5
6
7
8
9
5.4
5.6
5.8
6.0
6.2
6.4


Trichostatin.A Predicted vs Actual Efficacy
pathway only (R2= 0.28)
Actual Efficacy
4.5
5.5
4.4
4.6
4.8
5.0
5.2
Precticted Efficacy


Trichostatin.A Predicted vs Actual Efficacy
subtype only (R2= 0.39)
Actual Efficacy
4.5
5.5
4.6
4.7
4.8
4.9
5.0
5.1
5.2
Precticted Efficacy


Trichostatin.A Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.51)
Actual Efficacy
4.5
5.5
4.4
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


Tykerb.IGF1R..1.1. Predicted vs Actual Efficacy
pathway only (R2= 0.25)
Actual Efficacy
5.5
6.0
6.5
7.0
5.8
6.0
6.2
6.4
6.6
Precticted Efficacy


Tykerb.IGF1R..1.1. Predicted vs Actual Efficacy
subtype only (R2= 0.33)
Actual Efficacy
5.5
6.0
6.5
7.0
6.0
6.2
6.4
6.6
6.8
Precticted Efficacy


Tykerb.IGF1R..1.1. Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.42)
Actual Efficacy
5.5
6.0
6.5
7.0
5.8
6.0
6.2
6.4
6.6
6.8
Precticted Efficacy


VX.680 Predicted vs Actual Efficacy
pathway only (R2= 0.36)
Actual Efficacy
4.5
5.5
6.5
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
Precticted Efficacy


VX.680 Predicted vs Actual Efficacy
subtype only (R2= 0.12)
Actual Efficacy
4.5
5.5
6.5
5.3
5.4
5.5
5.6
5.7
5.8
Precticted Efficacy


VX.680 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.36)
Actual Efficacy
4.5
5.5
6.5
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
Precticted Efficacy


Valproic.acid Predicted vs Actual Efficacy
pathway only (R2= 0.31)
Actual Efficacy
2.2
2.6
3.0
3.4
2.6
2.7
2.8
2.9
3.0
Precticted Efficacy


Valproic.acid Predicted vs Actual Efficacy
subtype only (R2= 0.17)
Actual Efficacy
2.2
2.6
3.0
3.4
2.55
2.60
2.65
2.70
2.75
2.80
2.85
Precticted Efficacy


Valproic.acid Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.53)
Actual Efficacy
2.2
2.6
3.0
3.4
2.4
2.6
2.8
3.0
Precticted Efficacy


Velcade Predicted vs Actual Efficacy
pathway only (R2= 0.2)
Actual Efficacy
6.0
7.0
8.0
9.0
7.0
7.5
8.0
8.5
Precticted Efficacy


Velcade Predicted vs Actual Efficacy
subtype only (R2= 0.08)
Actual Efficacy
6.0
7.0
8.0
9.0
7.4
7.6
7.8
8.0
8.2
Precticted Efficacy


Velcade Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.45)
Actual Efficacy
6.0
7.0
8.0
9.0
6.0
6.5
7.0
7.5
8.0
8.5
9.0
Precticted Efficacy


Vinorelbine Predicted vs Actual Efficacy
pathway only (R2= 0.07)
Actual Efficacy
6
7
8
9
7.4
7.6
7.8
8.0
Precticted Efficacy


Vinorelbine Predicted vs Actual Efficacy
subtype only (R2= 0.11)
Actual Efficacy
6
7
8
9
7.4
7.6
7.8
8.0
Precticted Efficacy


Vinorelbine Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.25)
Actual Efficacy
6
7
8
9
6.5
7.0
7.5
8.0
Precticted Efficacy


XRP44X Predicted vs Actual Efficacy
pathway only (R2= 0.39)
Actual Efficacy
4.0
5.0
6.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


XRP44X Predicted vs Actual Efficacy
subtype only (R2= 0.04)
Actual Efficacy
4.0
5.0
6.0
5.6
5.7
5.8
5.9
6.0
Precticted Efficacy


XRP44X Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.39)
Actual Efficacy
4.0
5.0
6.0
4.5
5.0
5.5
6.0
6.5
Precticted Efficacy


ZM447439 Predicted vs Actual Efficacy
pathway only (R2= 0.21)
Actual Efficacy
4.0
5.0
6.0
4.5
5.0
5.5
Precticted Efficacy


ZM447439 Predicted vs Actual Efficacy
subtype only (R2= 0.16)
Actual Efficacy
4.0
5.0
6.0
4.6
4.8
5.0
5.2
5.4
Precticted Efficacy


ZM447439 Predicted vs Actual Efficacy
Pathway + subtype (R2= 0.21)
Actual Efficacy
4.0
5.0
6.0
4.5
5.0
5.5
Precticted Efficacy